Blog

  • Kerstin Lindblad-Toh receives major award from Swedish Research Council

    Paul Goldsmith, March 31st, 2014

    This week, Broad scientific director of vertebrate genome biology Kerstin Lindblad-Toh became one of the first recipients of a new long-term research grant from the Swedish Research Council. The program, known as Grants for Distinguished Professors, provides Swedish scientists with 10 years of flexible funding to support ambitious, long-term projects. Lindblad-Toh is one of only nine researchers selected to receive the inaugural award.

    0 Comments
    Read More
  • Insights into drug resistance for a rare leukemia

    Haley Bridger, March 3rd, 2014

    What: For patients with T cell acute lymphoblastic leukemia (T-ALL), a rare form of blood cancer that mainly affects children and young adults, drug resistance poses a major threat to a promising treatment option currently in clinical trials. About half of patients with T-ALL have mutations in NOTCH1, but drugs that target this gene have so far produced only short-lived effects: at first, the cancer seems to respond, but in a short period of time, T-ALL returns.

    0 Comments
    Read More
  • Setting the standard in proteomics

    Veronica Meade-Kelly, February 27th, 2014

    What: Members of the Broad’s Proteomics Platform were the lead authors of a recent paper that outlined best practices for developing and publishing studies involving one of the field’s signature tools: targeted mass spectrometry (MS).

    0 Comments
    Read More
  • Putting a neglected disease in the spotlight

    Paul Goldsmith, February 6th, 2014

    Heard of Chagas disease? Chances are, unless you live in Central or South America where the disease affects an estimated 8 million people, you probably haven’t.

    1 Comments
    Read More
  • Single driver mutation found in rare brain tumor

    Leah Eisenstadt, January 30th, 2014

    For patients with a rare brain tumor known as craniopharyngioma, the treatment options are slim — and often hazardous. Although the tumor is usually not aggressive, its location is perilous. Growing at the base of the skull near the pituitary gland, the tumor compresses parts of the brain as it enlarges, causing vision and learning problems and endocrine dysfunction, as well as morbid obesity. There is currently no drug to shrink the tumor, so the only options are surgical removal and radiation, which can leave patients with serious, lasting problems.

    0 Comments
    Read More
  • Ancestral legacy

    Veronica Meade-Kelly, January 29th, 2014

    It’s part of human nature: we look at ourselves in the mirror and see links to the past. “Those bright green eyes?” we think. “Those came from grandma.” “The cleft chin? That’s from dad’s side.” Our instinct, of course, is to attribute notable traits to close relatives – those that we know personally or through family history. The reality, however, is that the genetics that influence our traits – or “phenotypes” – could date back generations.

    0 Comments
    Read More
  • Broadies named to ‘30 under 30’

    Paul Goldsmith, January 10th, 2014

    The annual Forbes ’30 under 30’ was revealed this week, and two members of the Broad community, Cigall Kadoch and Aleksander Kostic, were named to the list. Now in its third year, ’30 under 30’ recognizes the brightest young talents in 15 different fields, including science and healthcare, technology and finance.

    0 Comments
    Read More
  • Charting the RNA epigenome

    Leah Eisenstadt, December 13th, 2013

    In science, sometimes you need to dive deep to see the big picture. Scientists at the Broad Institute have demonstrated this time and again, enabling biological discoveries by generating dense maps, such as the survey of thousands of epigenetic marks on DNA across the human genome conducted as part of the ENCODE project.

    0 Comments
    Read More
  • The drug works…but why?

    Veronica Meade-Kelly, December 11th, 2013

    What: A team led by Broad scientists has uncovered how the cancer drug lenalidomide works. Lenalidomide has been used for nearly a decade to treat multiple myeloma and other disorders that affect blood cells found in bone marrow, but its exact mechanism of action hadn’t previously been understood.

    0 Comments
    Read More
  • Holiday closing from Dec. 23, 2013 to Jan. 1, 2014

    Haley Bridger, December 6th, 2013

    To give employees ample time to celebrate the holidays with friends and family, the Broad Institute will close from Monday, December 23, 2013 to Wednesday, January 1, 2014. It will reopen on Thursday, January 2, 2014.

    Our websites, of course, will still be up and running during the closing, allowing researchers all over the globe to continue accessing data, software, tools, and more.

    0 Comments
    Read More